GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intervacc AB (OSTO:IVACC) » Definitions » Capex-to-Revenue

Intervacc AB (OSTO:IVACC) Capex-to-Revenue : 0.06 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Intervacc AB Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Intervacc AB's Capital Expenditure for the three months ended in Mar. 2024 was kr-0.14 Mil. Its Revenue for the three months ended in Mar. 2024 was kr2.39 Mil.

Hence, Intervacc AB's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.06.


Intervacc AB Capex-to-Revenue Historical Data

The historical data trend for Intervacc AB's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intervacc AB Capex-to-Revenue Chart

Intervacc AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.25 2.39 4.43 0.63 0.26

Intervacc AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.29 0.20 0.09 0.06

Competitive Comparison of Intervacc AB's Capex-to-Revenue

For the Biotechnology subindustry, Intervacc AB's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intervacc AB's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intervacc AB's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Intervacc AB's Capex-to-Revenue falls into.



Intervacc AB Capex-to-Revenue Calculation

Intervacc AB's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.107) / 8.015
=0.26

Intervacc AB's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.143) / 2.394
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intervacc AB  (OSTO:IVACC) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Intervacc AB Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Intervacc AB's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Intervacc AB (OSTO:IVACC) Business Description

Traded in Other Exchanges
Address
Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.

Intervacc AB (OSTO:IVACC) Headlines

No Headlines